Phase 2 Atopic Dermatitis Trial Fails; Aclaris Pivots to ITK Inhibitors and ATI-052
ACRS sits 67% above its 52-week low of $2.25 on light trading volume (0.4× avg).
Summary
The Phase 2 ADMIRATION trial of bosakitug (ATI-045), an anti-TSLP monoclonal antibody, missed both its primary endpoint — percent change in EASI score at week 24 — and all secondary endpoints in moderate-to-severe atopic dermatitis. Pharmacodynamic data showed target engagement and downregulation of Th1/Th2/Th17 biomarkers, and the drug was generally well tolerated, but efficacy failed. CEO Neal Walker said the result does not change development priorities: the company has started the Phase 2b ALPHA trial of oral ITK/JAK3 inhibitor modzatinib in lichen planus, with top line oral erosive lichen planus cohort results expected in the second half of 2027, expects to file the IND for ATI-9494 this quarter, and plans a Phase 2b trial of ATI-052 in eosinophilic esophagitis in Q1 2027. This is a clear setback for the anti-TSLP monotherapy program, though Aclaris is steering investors toward its oral kinase and bispecific assets. The company ended Q3 with $204.6M in cash and runway into the first half of 2029, so it is not financing-constrained near term. Watch the ATI-9494 IND filing this quarter and the ATI-052 eosinophilic esophagitis trial start in Q1 2027.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Aclaris initiated the Phase 2b ALPHA trial of modzatinib in lichen planus, with top line oral erosive lichen planus cohort results expected in the second half of 2027.
At the time of this announcement, ACRS was trading at $3.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $621.8M. The 52-week trading range was $2.25 to $6.60. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.